Hot off the press: |transkript 3/2024
|transkript, one of our German magazines, has been the leading industry publication for biotechnology and life sciences in German-speaking Europe since 1995. It covers current information, opinions, and background on business, research, and politics. In this issue:
As part of a National Gene and Cell Therapy Strategy, clinicians, manufacturers, biopharma companies, policymakers, and authorities aim to achieve what has so far seemed impossible in Germany: rapid technology transfer in a growth market. Following the symbolic launch and handover to the BMBF, the real work of implementing the strategy begins.
Other topics in this issue:
- AI, AI, AI – nothing works without artificial intelligence. Yet, first-generation AI firms are laying off staff. Is drug discovery still as high-risk as ever? Experts are betting on long-term transformation.
- Interview: Dr Bert Klebl, Managing Director and Scientific Head of Lead Discovery Center GmbH, Dortmund
- AC Immune: Swiss researchers leverage a new molecular variant for Alzheimer’s treatment
- Commission President Ursula von der Leyen presents plans for her second term – but omits biotechnology’s role
- Protests against the “Good Heart Act”
- Clear perspective: Martin Walger, VDGH
- Interview: Prof. Dr Christof von Kalle, Director of the Clinical Study Centre, BIH Charité, Berlin
- Combination therapy doubles survival in high-risk neuroblastoma cases
- Real-time kidney test nearing approval
- Gene therapy: combating myelin loss
- Business leaders turn to SynBio
- |transkript personal: Jiri Friml, Professor at the Institute of Science and Technology Austria (ISTA) and winner of this year’s “Austro-Nobel Prize”
- Medtech-zwo, start-ups, network insights, stock market updates
- Laborwelt: Zellbiologie
Read the issue here (in German).